Objective: To explore the mechanism of ginsenoside Rb1 in the treatment of Parkinson 's disease by using network pharmacology technology, and to provide scientific theoretical basis for the clinical rational application of ginsenoside Rb1. Methods: The targets of ginsenoside Rb1 were predicted in SwissTargetPrediction, SEA and SuperPred databases. The related targets of Parkinson's disease were obtained in the GeneCards and Omim databases using the keyword 'Parkinson Disease'. The ginsenoside Rb1 and the target of Parkinson's disease were mapped to each other, and the Veen diagram was made to obtain the intersection gene. Then, Cytoscape 3.8.2 software was used to construct the 'drug-target' network ; the 21 common drug targets related to Parkinson's disease in the Venn diagram were imported into the String (https://string-db.org/) database for protein-protein interaction prediction, so as to predict the core targets. The core targets of ginsenoside Rb1 in the treatment of Parkinson's disease were imported into the DAVID database to obtain GO analysis results and KEGG enrichment results. AutoDock Vina was used to perform molecular docking between ginsenoside Rb1 and key targets to verify their interaction activity. Results: There were four core targets of ginsenoside Rb1 in the treatment of Parkinson's disease, namely BCL2L1, VEGFA, FGF2, KDR, with 28 related pathways. Combined with the biological characteristics of ginsenoside Rb1, it was found that ginsenoside Rb1 treatment of Parkinson's disease mght be involved in the biological regulation process through the PI3K/Akt signaling pathway, and this regulation process was closely related to the mechanism of apoptosis in cell bioengineering. Through the molecular docking verification of the key target and ginsenoside Rb1, the target interaction was highly combined. Conclusion: The mechanism of ginsenoside Rb1 in the treatment of PD may play a role by reducing the biological process of apoptosis. The related pathways affected are PI3K/Akt signaling pathway, MAPK signaling pathway, Notch signaling pathway, and BCL2L1, VEGFA, FGF2, KDR and other targets.
ZHU Hongbo
,
DAI Yujing
,
ZHAO Jie
,
HUO Dongsheng
. The mechanism of ginsenoside Rb1 in the treatment of Parkinson's disease based on network pharmacology[J]. Journal of Baotou Medical College, 2024
, 40(6)
: 7
-13
.
DOI: 10.16833/j.cnki.jbmc.2024.06.002
[1] Dorsey ER,Sherer T, Okun MS, et al. The emerging evidence of the parkinson pandemic[J]. Parkinsons Dis, 2018,8(s1):S3-S8.
[2] Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson’s disease[J]. Mol Brain, 2017,10(1):53.
[3] 宋悦,刘森洋,高宇,等. 人参皂苷Rb1抗炎作用及其机制研究进展[J]. 中国医学创新,2023,20(1):173-178.
[4] 刘博,俞婷,韩晓蕾,等. 人参皂苷抗炎作用及其分子机制的研究进展[J]. 中国药学杂志,2019,54(4):253-258.
[5] 耿艺娟,孙梦桢,赵进东,等. 人参皂苷Rb1对MPTP诱导的神经元损伤和小鼠行为学异常的作用研究[J]. 天然产物研究与开发,2022,34(5):842-847.
[6] 毛丽斯,朱晓红. 网络药理学在中药领域的应用进展[J]. 中医药管理杂志,2021,29(13):98-102.
[7] 王子怡,王鑫,张岱岩,等. 中医药网络药理学:《指南》引领下的新时代发展[J]. 中国中药杂志,2022,47(1):7-17.
[8] 汪亚楠,李思齐,岳一强,等. 基于网络药理学的苓桂术甘汤治疗阿尔茨海默病的潜在作用机制研究[J]. 中草药,2019,50(23):5812-5822.
[9] Safran M, Dalah I, Alexander J, et al. GeneCards Version 3:the human gene integrator[J]. Database, 2010,2010:baq020.
[10] Amberger JS,Bocchini CA,Schiettecatte F,et al. OMIM.org:online Mendelian Inheritance in Man (OMIM), an online catalog of human genes and genetic disorders[J]. Nucleic Acids Res, 2015,43(Database issue):D789-D798.
[11] Szklarczyk D, Gable AL, LYON D, et al. String v11:protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019,47(D1):D607-D613.
[12] Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists[J]. Nucleic Acids Res, 2009,37(1):1-13.
[13] 侯兵乔,刘荣瑜,王迪,等. 基于网络药理学及分子对接探讨青龙衣抗胃炎作用的潜在靶点和分子机制[J]. 中国药学杂志,2023,58(7):599-610.
[14] 朱成姗,李子寒,彭洪兵,等. 基于网络药理学和睾丸间质细胞模型探讨恩施巴戟促进睾酮分泌的作用机制[J]. 中草药,2022,53(23):7430-7439.
[15] 李坤,马壮士,董玲芳,等. 基于网络药理学和分子对接探讨慈丹胶囊治疗肝癌的作用机制[J]. 中国临床药理学杂志,2022,38(22):2766-2770.
[16] Fu Y, Xing RR, Wang LL, et al. Neurovascular protection of salvianolic acid B and ginsenoside Rg1 combination against acute ischemic stroke in rats[J]. Neuroreport, 2021,32(13):1140-1146.
[17] 杨常青,韩芳芳,袁菲,等. 人参皂苷Rb1抑制利多卡因诱导小鼠原代脊髓神经干细胞损伤研究[J]. 安徽医科大学学报,2020,55(9):1332-1338.
[18] 魏山山,王孟迪,姜宁,等. 人参皂苷Rg1、Rb1、Rg1+Rb1改善东莨菪碱致小鼠认知障碍的作用比较[J]. 中国比较医学杂志,2022,32(4):94-101.
[19] 姚远,杜静怡,周文娟. 人参皂苷Rb1促进小鼠坐骨神经损伤修复的作用及机制[J]. 解剖学报,2022,53(1):19-27.
[20] 罗荣卿,胡玉英. PI3K/Akt信号通路与帕金森病相关性及中医药治疗概述[J]. 山东中医杂志,2021,40(12):1379-1383.
[21] 周怡言,曾宪峰,刘鑫鑫. miR-221靶向PTEN介导PI3K/AKT信号通路调节细胞自噬参与帕金森病的机制研究[J]. 脑与神经疾病杂志,2021,29(7):411-417.
